Skip to main content

Table 4 Patient characteristics of the study population in the 4th supplementary analysis

From: Impact of the interval between neoadjuvant concurrent chemoradiotherapy and esophagectomy in the modern era: a population-based propensity-score-matched retrospective cohort study in Asia

 Short interval (n = 63)Long interval (n = 63) 
Number or
mean (sd)
(%)Number or
mean (sd)
(%)SDif
Age 54.17 (8.22) 54.46 (8.63) 0.034
GenderFemale0
Male 
ResidencyNon-north43(68)39(62)0.133
North20(32)24(38) 
Tumor size≤ 5 cm17(27)20(32)0.105
> 5 cm46(73)43(68) 
Tumor differentiationPoorly/undifferentiated14(22)18(29)0.146
Well/moderately49(78)45(71) 
RT deliveryNon-IGRT51(81)53(84)0.084
IGRT12(19)10(16) 
Use of PETNo9(14)8(13)0.046
Yes54(86)55(87) 
Tumor locationCervical0
Non-cervical 
T-stageT1–T28(13)8(13)0
T3–T455(87)55(87) 
N-stageNegative6(10)6(10)0
Positive57(90)57(90) 
DrinkingNo8(13)8(13)0
Yes55(87)55(87) 
Betel nut chewingNo27(43)27(43)0
Yes36(57)36(57) 
SmokingNo10(16)9(14)0.044
Yes53(84)54(86) 
BMI 21.84 (3.40) 22.07 (3.39) 0.07
Number of LNs< 1512(19)15(24)0.116
≥ 1551(81)48(76) 
RT dose (Gy) 48.30 (3.47) 47.59 (3.54) 0.205
Patient volumeLow volume23(37)20(32)0.101
High volume40(63)43(68) 
Positive LN 0.70 (1.29) 0.75 (1.75) 0.031
  1. BMI body mass index, IGRT image-guided radiotherapy, LN lymph node, nCCRT neoadjuvant concurrent chemoradiotherapy, PET positron emission tomography, RT radiotherapy, sd standard deviation, SDif standardized difference
  2. Rounded
  3. The exact numbers were not reported because of a Health and Welfare Data Science Center (HWDC) database center policy to avoid numbers in single cells (≤ 2)